Ketamine Therapy with Diabetes: Metformin, GLP-1, Insulin (2026)

If you have type 1 or type 2 diabetes and you're considering ketamine therapy, the honest summary upfront: well-controlled diabetes is fully compatible with at-home ketamine therapy. The conversation is less about whether to do treatment and more about the practical timing — when to take your medications, how to handle the pre-session fast safely, and which medication classes need a specific adjustment around session days.

Depression and anxiety are notably more common in people with diabetes than in the general population (estimates run roughly 2 to 3 times the rate of depression in T2D, and meaningfully elevated in T1D, with the day-to-day burden of glucose management contributing to a "diabetes distress" pattern that overlaps with depression without being identical to it). Many of the patients who arrive at ketamine therapy with treatment-resistant depression are also managing diabetes. This post is the version of the conversation we have at intake.

The short version

For most patients with diabetes:

• Metformin: continue on normal schedule. No interaction with ketamine.
• Insulin: adjust on session days to account for the 6-hour pre-session fast. Specifics differ for T1D vs T2D.
• GLP-1 agonists (Ozempic, Mounjaro, Wegovy, Zepbound): continue, but the gastric-emptying-delay matters for nausea management.
• SGLT2 inhibitors (Jardiance, Farxiga, Invokana): continue on the normal schedule; shorten the pre-session fast from 6 hours to 4 hours instead of holding the drug.
• Sulfonylureas (glipizide, glyburide, glimepiride): hold the dose before a fasted session to avoid hypoglycemia.
• Continuous glucose monitor (CGM): keep it on during the session. It's a useful safety tool.

The detail behind each of those bullets is below.

How ketamine and diabetes interact pharmacologically

There is no direct ketamine-glucose interaction at therapeutic sublingual doses. Ketamine doesn't raise or lower blood sugar in any meaningful way for at-home dosing. The pre-session fast is the variable that matters; the medication that helps you manage glucose is the other variable.

In high-dose anesthesia ketamine (IV ketamine in surgical settings) there is some literature on transient cortisol-mediated hyperglycemia, but the doses are an order of magnitude higher than at-home therapeutic sublingual doses and the duration is much longer. For a 90-minute home session at therapeutic dose, glucose effects are clinically negligible. The safety conversation is entirely about the fast and the medications around it.

The 6-hour pre-session fast: T1D vs T2D

Standard at-home ketamine protocol asks for a 6-hour fast before the session to reduce nausea and aspiration risk during the dissociative period. For diabetic patients, "fasted" doesn't mean unmanaged — it means adjusting your medication plan so your blood sugar stays in a safe range across those 6 hours plus the 2-3 hour session.

Type 2 diabetes (most patients)

For T2D patients on oral medications and/or once-daily basal insulin:

• Standard morning routine is usually fine if your session is in the late afternoon or evening (which is the default scheduling for at-home ketamine).
• Eat a normal breakfast and a moderate, glucose-stable lunch ending at least 6 hours before the session start time.
• Hold your pre-dinner basal or rapid insulin if you'd normally take it with the meal you're skipping. Discuss specific timing with your physician.
• Sulfonylureas (glipizide, glyburide, glimepiride): hold the morning dose if your fast will extend through the typical mealtime — these drugs continue stimulating insulin release for hours and can drop sugar dangerously during a fast.
• Glucose check 30-60 minutes before the session. If below 90, eat a small carbohydrate snack 30 minutes before dosing and recheck. Below 70 is a deferral.

Type 1 diabetes (more individualized)

T1D requires a more individualized plan, ideally coordinated with the endocrinologist managing your insulin. The session-day approach typically involves:

• Continue basal insulin at the normal dose. Cutting basal in T1D rapidly produces hyperglycemia and ketosis.
• Bolus insulin: only if you eat. Hold meal-time rapid-acting insulin for the meals you're fasting through.
• Glucose check at session start, and a hand-warm orange juice or glucose tab kept within arm's reach in case sugar drops during the session.
• CGM data shared with your sitter so the peer supervisor can monitor a low without waking you out of the experience.
• Sliding-scale insulin: defer corrections during the session itself; address pre- and post-session.
• Target glucose at session start: 100-180 mg/dL. Outside that range, reschedule.

T1D patients have done at-home ketamine safely many times, but the plan needs to be built in advance with the endocrinologist, not improvised the morning of.

Specific medication classes worth knowing

Metformin

Compatible with ketamine therapy. No interaction at therapeutic doses. The historical concern about lactic acidosis with metformin is real but unrelated to ketamine specifically; it applies to renal-failure or acute-illness contexts. Continue metformin on your normal schedule. If you take metformin with breakfast and lunch and your session is afternoon, no adjustment needed.

GLP-1 agonists (Ozempic, Mounjaro, Wegovy, Zepbound, Trulicity, Rybelsus)

This class has exploded in 2024-2026 for both T2D and weight management, and a growing fraction of new patients are on one. The relevant interactions:

• Gastric emptying delay. GLP-1s slow stomach emptying, which means food eaten 6 hours before the session may still be partially undigested at session start. The aspiration-risk concern that led anesthesiologists to recommend holding GLP-1s 1-2 weeks before surgical procedures applies here too at a lower magnitude. Most at-home prescribers don't ask patients to hold GLP-1s for sessions, but they DO ask patients to extend the fast to 8 hours instead of 6 if currently on one.
• Increased nausea risk during the session. GLP-1s alone cause nausea in 20-40% of patients; ketamine has its own nausea profile. Stacked, some patients see meaningful session-day nausea. Pre-session ondansetron (Zofran) is often added.
• Glucose effects are gentler. GLP-1s don't typically cause hypoglycemia on their own (unlike insulin or sulfonylureas), so the fasting math is less risky for patients on GLP-1 monotherapy.

If you're on a weekly injectable GLP-1 (Ozempic, Wegovy, Mounjaro, Zepbound), schedule your session for the day of the week with the lowest GLP-1 levels — usually the day before your next injection, when the drug has had a full week to decline. Continue the injection on the normal schedule; don't change it for ketamine.

SGLT2 inhibitors (Jardiance, Farxiga, Invokana, Steglatro)

The textbook concern with SGLT2s and ketamine sessions is euglycemic diabetic ketoacidosis — DKA at normal-looking blood sugar levels, easy to miss. SGLT2 inhibitors shift metabolism in a way that increases ketone production, prolonged fasting also increases ketone production, and the combination plus a stressor can in rare cases tip a patient into DKA. That's why some clinics ask SGLT2 patients to hold the drug 24-48 hours before a session.

In practice that's overly cautious for at-home therapeutic ketamine. The protocol I use:

• Continue the SGLT2 on its normal schedule. No need to skip doses.
• Shorten the pre-session fast from 6 hours to 4 hours. A 4-hour gap is a normal physiologic interval between meals — short enough that it doesn't drive meaningful ketogenesis, long enough to manage aspiration risk at therapeutic at-home doses.
• Drink water with a small amount of electrolytes during the 4-hour window. SGLT2s mildly dehydrate.
• For T1D patients on an SGLT2 (off-label use), coordinate with your endocrinologist before the first session. T1D is independently more DKA-prone, so the planning conversation is more involved.

The mechanism that makes the 24-hour hold "safer" on paper is the same mechanism that makes a 4-hour fast safer in practice: less fasting time, less ketone accumulation, less euglycemic DKA risk. Shortening the fast is the simpler lever and doesn't ask the patient to interrupt a glucose-lowering medication.

Insulin pump and CGM users

• CGM stays on. It's a useful safety tool during the session — the peer supervisor can glance at the receiver or phone without disturbing the patient.
• Insulin pump basal continues at the normal rate unless your physician has specifically adjusted it.
• Bolus through the pump for any pre-session carb correction if needed; otherwise hold corrections during the dissociative period.
• Pump alarms should be turned on at audible levels so a low triggers an alert the sitter can hear.

Steroids (prednisone, dexamethasone, hydrocortisone)

If you're on steroids for diabetes-related complications (rare but happens — eye conditions, autoimmune comorbidity), the steroid-induced hyperglycemia they produce needs accounting for. Continue the steroid on normal schedule; expect glucose to run high through the session; don't try to correct aggressively during the dissociative period.

Why depression and diabetes travel together

The comorbidity is well established. Adults with T2D have roughly 2-3× the rate of major depression compared to the general population; T1D rates are similarly elevated. Several mechanisms drive the overlap:

• Diabetes distress. The daily burden of glucose checks, food decisions, medication timing, and worrying about long-term complications wears down baseline mood. This is a real phenomenon distinct from major depression but contributing to its prevalence in diabetic populations.
• Shared inflammatory pathways. Both depression and T2D have inflammation as a contributor; the biology overlaps.
• Sleep disruption. Nocturnal hypoglycemia, frequent waking for glucose checks, and the metabolic effects of poor glycemic control all degrade sleep, which feeds depression.
• Sedentary patterns. Depression reduces physical activity; reduced activity worsens glucose control; worse glucose control feeds the cycle.
• Medication side effects. Some diabetes medications affect mood, energy, or appetite in ways that can present like depression.

Stimulant medication for ADHD doesn't treat depression; metformin doesn't treat depression; SSRIs help but a meaningful subset of diabetic patients don't respond adequately. Ketamine sits in that gap for many of these patients — treating the depression layered on top of diabetes management without affecting glucose control directly.

What good candidacy looks like

The patient profiles I see comfortably do at-home ketamine therapy:

• Well-controlled T2D (A1c under 8.0, ideally under 7.0) on oral medications, with stable medication regimen for several months
• Stable T1D with established CGM use, working with an endocrinologist who can coordinate session-day insulin planning, A1c under 8.5
• GLP-1 user for T2D or weight management with stable glucose, willing to use ondansetron for session-day nausea management
• Diabetic with treatment-resistant depression that hasn't responded to 2+ adequate antidepressant trials — the classic candidacy story
• Patient with diabetes distress + diagnosable depression where the mood component is impairing function

When to defer or shift to a different pathway

Less common but real:

• A1c above 9 — significantly uncontrolled diabetes. Get glucose under better control first, then start ketamine.
• Recurrent hypoglycemia or hypoglycemia unawareness — too unpredictable for a fasted session.
• Active DKA history within the last 6 months — needs endocrinology stabilization before adding a new variable.
• Severe diabetic neuropathy with cardiovascular dysautonomia — the autonomic instability stacks with ketamine's transient sympathetic activation; talk to your prescriber about whether in-clinic monitoring is more appropriate.
• Diabetic gastroparesis — meaningful gastric-emptying delay means the standard 6-hour fast may not be enough; this needs individualized planning or an in-clinic alternative.
• Active diabetic ulcer or infection — manage the acute issue first.

These aren't permanent disqualifiers — they're "address the diabetes side first, then come back" situations.

Frequently Asked Questions

Can you take ketamine with metformin?

Yes. Metformin and ketamine have no significant interaction at therapeutic doses. Continue metformin on your normal schedule. The historical concern about metformin and lactic acidosis applies to renal failure or acute illness contexts, not ketamine therapy. This is one of the easiest medication combinations in the comorbidity guide.

Can you take ketamine with Ozempic, Mounjaro, or other GLP-1 agonists?

Yes, with two adjustments. First, extend the pre-session fast from 6 to 8 hours because GLP-1s delay gastric emptying. Second, expect somewhat more session-day nausea (both drugs cause nausea independently); pre-session ondansetron (Zofran) is commonly added to the protocol. Schedule the session on the day of the week with the lowest GLP-1 levels (typically the day before your next weekly injection). Don't change the GLP-1 dose or timing for ketamine.

Should I stop my SGLT2 inhibitor before a ketamine session?

No, continue your SGLT2 inhibitor (Jardiance, Farxiga, Invokana, Steglatro) on its normal schedule. The euglycemic DKA concern with SGLT2s and ketamine is driven by ketone accumulation during prolonged fasting. Rather than holding the medication for 24-48 hours, the simpler protocol is to shorten the pre-session fast from 6 hours to 4 hours — a normal physiologic gap between meals that doesn't drive meaningful ketogenesis. Drink water with electrolytes during the fast. For T1D patients on an SGLT2 (off-label use), coordinate the plan with your endocrinologist; T1D is independently more DKA-prone regardless of SGLT2 status.

How do I handle insulin on a ketamine session day?

For T2D: continue basal insulin normally, hold meal-time rapid-acting insulin for any meals you're fasting through, check glucose 30-60 minutes pre-session, target 100-180 mg/dL at start. For T1D: continue basal at normal dose (don't cut — risks hyperglycemia and ketosis), hold bolus insulin only for missed meals, keep a fast-acting carb source within arm's reach during the session, share CGM data with your peer supervisor so they can monitor lows. T1D plans should be built in coordination with the endocrinologist managing your insulin regimen.

Can you take ketamine with sulfonylureas (glipizide, glyburide, glimepiride)?

Yes, but hold the dose that would have been taken with the meal you're fasting through. Sulfonylureas continue stimulating insulin release for hours; taking them during a fast significantly raises hypoglycemia risk. If your session is afternoon and you're skipping lunch, hold the morning sulfonylurea dose or take a small carb snack with it to bridge the fast.

Can you do ketamine therapy with type 1 diabetes?

Yes, with a coordinated plan with your endocrinologist. T1D patients have done at-home ketamine safely many times. Key requirements: established CGM use, target glucose 100-180 at session start, basal insulin continued, bolus held for fasted meals, fast-acting carb within reach, peer supervisor briefed on glucose monitoring. A1c under 8.5 and stable.

What if my A1c is high?

Above 9.0, get diabetes management improved before starting ketamine — both because uncontrolled diabetes adds risk to any new treatment and because the patient's bandwidth for managing a new protocol is limited when glucose is unstable. 7.0-9.0 is generally fine with the standard cautions; under 7.0 is fully unrestricted.

Is hypoglycemia during a ketamine session dangerous?

Potentially, yes, which is why the peer supervisor and CGM matter for diabetic patients. The dissociative experience can mask the subjective symptoms of a low (sweating, shakiness, anxiety), which is why we don't rely on patient self-report during the session itself. The CGM + a sitter who knows what to look for is the safety mechanism. A glucose tab or juice within arm's reach lets the sitter intervene quickly without disrupting the experience more than necessary.

Do I need a CGM to do ketamine if I have diabetes?

Not strictly required, but strongly recommended for insulin-dependent patients (T1D and insulin-using T2D). For T2D patients on oral medications only (no insulin, no sulfonylureas), a basic glucose meter check pre- and post-session is sufficient. The CGM is most valuable for the population whose glucose can drop unpredictably during a fast.

Will ketamine help with diabetes distress and depression?

Often, yes. The depressive component of "diabetes distress" responds to ketamine on the same timeline as classic treatment-resistant depression: improvement within 24-72 hours of the first session, progressive gains across a 4-8 week induction. Ketamine doesn't change glucose control or remove the burden of daily management, but it can meaningfully reduce the depressive weight of carrying that burden. Many patients report that the mental energy they used to spend managing diabetes distress becomes available for actually managing the diabetes better — a virtuous cycle.

Ready to See Where You Stand?

If you have diabetes and want to know whether at-home ketamine therapy fits your specific situation, I'm here to take a look. Dr. Ben Soffer is a board-certified physician with internal medicine training; diabetes management coordination is core to that work, especially for patients on insulin, GLP-1 agonists, or SGLT2 inhibitors. Every intake includes a review of your current diabetes regimen and a session-day plan before any prescription is issued.

For the cardiovascular and metabolic side of the comorbidity picture, see ketamine therapy with high blood pressure, ketamine therapy with heart disease, and ketamine therapy with liver disease. For the broader medication-interaction picture, see medication safety with ketamine. For Spravato as an alternative, see Spravato 2026 update.

The five-minute eligibility check will give you a quick read on whether your current diabetes regimen fits the at-home protocol or warrants additional planning with your endocrinologist first.